Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M14D1 + Atezolizumab in Extensive-stage Small Cell Lung Cancer
NCT07654400Phase 2Recruiting
- Sponsor
- Sichuan Biokin Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BL-M14D1 in small cell lung cancer (SCLC), sponsored by Sichuan Biokin Pharmaceutical. Primary endpoints: Objective Response Rate at 12 months and Treatment-Emergent Adverse Event at 12 months. Started Jul 2026; status: recruiting.
02
Drugs
BL-M14D1
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07654400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654400.